Coeptis Therapeutics Inc Stock Price, News & Analysis

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced its rebranding to COEPTIS, signaling a strategic expansion beyond biopharmaceuticals into technology-driven sectors. The company has established a new Technology Division, marked by the acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution.

The transformation aims to enhance operational capabilities and maximize shareholder value through technology integration. The NexGenAI platform will provide AI-driven marketing solutions for highly regulated industries, while the Technology Division focuses on developing automation capabilities and AI agents to optimize workflows.

According to CEO Dave Mehalick, this strategic shift aims to create revenue-generating, cash flow-positive business units, positioning COEPTIS as a self-sustaining entity. The company's technology suite includes AI-driven marketing software, robotic process automation (RPA), and data analytics tools designed to enhance communication strategies and drive sustainable growth.

Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has announced the expansion of its technological initiatives to include artificial intelligence and blockchain solutions. Following the successful launch of its Technology Division, the company aims to enhance operational efficiency and customer engagement through these advanced technologies.

CEO Dave Mehalick expressed enthusiasm about building upon the momentum generated by their Technology Division, particularly in AI, while exploring blockchain opportunities. The company views this expansion as a strategic move to remain at the forefront of technological developments and adapt to the evolving digital marketplace.

Coeptis Therapeutics Holdings (Nasdaq: COEP) announced it has regained compliance with Nasdaq's Listing Rule 5550(a)(2), known as the 'Bid Price Rule', following the Nasdaq Hearings Panel's decision from September 17, 2024. This development represents a positive start for the biopharmaceutical company, which focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the initial rollout of its NexGenAI Affiliates Network platform, securing five new customers with a total contract value of $1.7 million. The company has signed multiple Managed Services Agreements valued at $1.25 million with an anticipated recurring monthly revenue stream of $450,000.

The NexGenAI platform integrates AI-driven marketing software, robotic process automation (RPA), and data analytics to optimize campaigns and streamline operations. The platform features include AI Dialer Service, AI SMS Service, and RPA Assistance for marketing, recruitment, investment, and affiliate services.

CEO Dave Mehalick expressed optimism about the platform's early adoption and outlined plans for rapid rollout throughout 2025. The company expects significant growth through additional contracts with prospective clients currently under discussion.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a 1-for-20 reverse stock split effective December 31, 2024. Upon implementation, every 20 shares of outstanding common stock will be converted into one share, with fractional shares rounded up to the next whole number. The reverse split aims to help the company meet Nasdaq Capital Market's minimum bid price requirement of $1.00 per share.

The split was approved by stockholders on December 18, 2024, and will not alter stockholders' percentage interest in the company's outstanding common stock, except for adjustments from fractional share treatment. Continental Stock Transfer is serving as the exchange agent, with stockholders holding shares in brokerage accounts not required to take any action.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the acquisition of the NexGenAI Affiliates Network platform and launched Coeptis Technologies, marking a strategic expansion into AI-powered solutions. The platform, developed by NexGenAI Solutions Group, provides AI-powered marketing software and robotic process automation (RPA) capabilities designed for the biotech, pharmaceutical, and multi-level marketing industries.

The acquisition aims to enhance marketing optimization, customer engagement, and operational efficiency in highly regulated sectors. The company views this integration as a strategic move to leverage advanced technologies within the biopharmaceutical sector and provide innovative tools for companies facing marketing challenges in competitive industries.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the launch of Coeptis Technologies, a new division aimed at diversifying its business beyond biopharmaceuticals. The company has signed a binding Letter of Intent to acquire key assets from a Risk Mitigation Software Company with 10,000 customers across 100 countries.

The acquisition includes proprietary technologies such as Data Placement Manager and Sensitive Content Manager solutions. This move follows the upcoming acquisition of NexGenAI Affiliates Network, positioning Coeptis in the data security and AI technology sectors. The Risk Mitigation Software Company's CEO will join Coeptis to lead the new technology division, with the transaction expected to close in early 2025.

Coeptis Therapeutics Holdings (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, a platform offering AI-powered marketing software and robotic process automation (RPA) capabilities. The acquisition aims to enhance Coeptis's operational efficiency while maintaining its focus on biopharmaceutical innovation. NexGenAI's suite of marketing tools utilizes AI and RPA to optimize campaigns, streamline workflows, and generate insights, particularly targeting the biotech, pharmaceutical, and multi-level marketing industries. The platform helps companies manage marketing campaigns while maintaining regulatory compliance.

Coeptis Therapeutics announced the acceptance of Phase 1 study results for DVX201, an allogeneic natural killer (NK) cell therapy, in Molecular Therapy Methods and Clinical Development. The study evaluated DVX201 for treating hospitalized COVID-19 patients at high risk for disease progression. Key findings showed DVX201 was safe and well-tolerated in 9 patients, with no dose-limiting toxicities or cytokine release syndrome. The therapy, derived from pooled donor cord blood CD34+ cells, demonstrated rapid improvements in oxygenation, improved pulmonary radiographic findings, and led to hospital discharge within days of infusion.